Resources Top 5: Gold Road to join the Gold Fields superhighway
Gold Road has relented to an offer from Gold Fields in a $3.7 billion buyout
Trigg Minerals has increased the antimony potential of Wild Cattle Creek deposit at the Achilles project
Porphyry copper-gold was intersected by Waratah Minerals in maiden drilling at Breccia West
Your standout resources stocks for Monday, May 5, 2025
Gold Road Resources (ASX:GOR)
One of the 'worst kept secrets' in the gold M&A scene has been thrown out in the open with Gold Road Resources relenting to a 'best and final' offer from Gold Fields in a $3.7 billion buyout.
The South African giant will swallow up its junior JV partner in the Gruyere gold mine in a scheme implementation deed that comes at a 43% premium to GOR's price before Gold Fields threw a previous $3.3bn cash bid out in the open.
The specifics are thus: Gold Road shareholders will claim $2.52 per share PLUS cash consideration equivalent to GOR's stake in Northern Star Resources – currently priced at 88c – something that will come into play after NST completes its now approved takeover of Hemi gold mine owner De Grey Mining.
If the scheme becomes effective GOR shareholders are also expected to roll in a 35c per share special dividend (give or take) worth $379m, using up the company's remaining franking credits.
7.5% of GOR shareholders have confirmed they intend to vote in favour of the scheme, and its Tim Netscher chaired board has agreed to the deal unanimously after some mud slinging around an 'opportunistic' offer in March that Gold Fields elected to air publicly.
'The board has been focused at all times on ensuring that we deliver value and act in the best interests of our shareholders. The Gold Road directors consider that the value offered by the all-cash scheme consideration delivers compelling value for Gold Road shareholders compared to what may otherwise be available if Gold Road continued to operate as a standalone entity,' Netscher said.
'The variable cash consideration provides ongoing exposure to the supportive gold price environment up until the effective date of the scheme through Gold Road's shareholding in Northern Star. Additionally, the payment of a special dividend allows Gold Road to realise the full value of the company's franking account balance for eligible shareholders.
'This cash proposal accelerates realisation of Gruyere's value and provides certainty for Gold Road shareholders today at an attractive premium to trading levels prior to receipt of the initial Gold Fields proposal.'
FIRB approval is required but the Aussie Govt tends to find South African investment is lekker. If approved it all goes ahead by October, crystallising a near 40x gain for GOR holders who bought in before the Gruyere discovery was made in the remote Yamarna Belt east of Laverton in October 2013.
$30bn capped Gold Fields will produce more than 1Moz in WA once the deal clears across its Gruyere, Granny Smith, St Ives and Agnew mines.
It's the latest M&A action to light up a gold space flying with Aussie prices in excess of $5000 an ounce. That includes the aforementioned NST-DEG tie-up, a $4.2bn merger between Ramelius Resources and Spartan Resources, $1bn deal to partner Alkane Resources and TSX-listed Mandalay and a host of asset level deals from Greatland Gold, Resolute Mining and more.
Trigg Minerals (ASX:TMG)
After increasing the antimony potential at the Wild Cattle Creek deposit of its Achilles project in northern NSW, Trigg Minerals has lifted 9.5% to 4.7c.
High-grade antimony assays have been returned from samples taken within an historical underground adit at the deposit.
Wild Cattle Creek is Australia's highest-grade primary antimony resource at 1.52Mt at 1.97% antimony, comprising 960,000t at 2.02% in the indicated category and 560,000t at 1.88% inferred.
The historical sample locations and corresponding antimony grades averaging 4.83% appear to have been accurately plotted on a drive plan and were included in an earlier resource estimate and preliminary feasibility report for Dundee Mines.
However, the assays were not included in a 2024 revised resource estimate, providing additional upside and strong potential for resource growth by Trigg.
Notable antimony intersections include 5.32m at 6.7% Sb, 5.42m at 9.6% Sb, 3.64m at 7.3% Sb, 2m at 12.7% Sb and 5m at 3.5% Sb.
Trigg Minerals (ASX:TMG) said the samples confirmed the presence of shallow, high-grade mineralisation within the deposit, suggesting the potential for higher overall grades than those indicated by drilling alone.
The results also reinforce the deposit's geological continuity and potential for early-stage extraction.
"The high-grade results strongly validate the continuity and tenor of antimony mineralisation at Wild Cattle Creek,' managing director Andre Booyzen said.
'These outcomes reinforce our confidence that substantial high-grade mineralisation remains accessible at shallow depths, supporting our broader development strategy, and may inform future mine design by highlighting the potential for early, low-cost extraction."
Significant intersections have also been returned from the parallel Roula lode which were not included in the resource estimate, including 2m at 11.57% Sb and 1.26% tungsten, and 2m at 14.45% Sb and 0.84% W, including 1m at 27.6% Sb
Adit mapping and sampling provide strong evidence for lode repetition along strike and subparallel, complementary lodes, indicating broader structural complexity and exploration upside.
Trigg plans to update the Wild Cattle Creek resource by incorporating unmodelled data to capture additional value from tungsten and gold alongside antimony.
Waratah Minerals (ASX:WTM)
A positive move has been made by Waratah Minerals after porphyry copper-gold was intersected in maiden drilling at Breccia West in the Spur project, 5km west of the giant Cadia Valley project of Newmont in Central West NSW, with shares up by 25% to 25c.
New drilling has intersected broad porphyry copper-gold mineralisation associated with potassic altered magmatic-hydrothermal breccia at Breccia West, with hole BZD001 returning 196m at 0.54% copper equivalent from 1m. This included 0.35% Cu and 0.23g/t Au.
Within this was 84m at 0.62% CuEq (0.40% Cu, 0.26g/t Au) from 29m and this also included 12m at 1.03% CuEq (0.65% Cu, 0.44g/t Au) from 185m.
Another hole, BZD002, identified a separate zone of porphyry mineralisation associated with strongly developed magnetite-rich potassic alteration hosted in basaltic wallrock along strike from a strong magnetic anomaly.
Given the strong association with magnetite, a high priority follow-up 'porphyry core' drill target is defined by a nearby magnetic anomaly and down dip projection of the mineralised magmatic- hydrothermal breccia.
'Intersecting porphyry mineralisation on our maiden drilling program at Breccia West strongly validates the company's exploration strategy and our view that the large area of epithermal gold mineralisation at the Spur Gold Corridor connects with a mineralised porphyry system,' managing director Peter Duerden said.
'The strong association of mineralisation with magnetite porphyry alteration has upgraded the significance of a nearby magnetic anomaly at the down dip, along strike projection of the mineralised magmatic-hydrothermal breccia and forms a compelling follow up 'porphyry-core' drill target.'
Follow up drilling of this target will be conducted alongside drilling activity at the Spur Gold Corridor where a large epithermal system is being defined with similarities to sections of the Cadia Valley project, which hosts 50Moz of gold and 9.5Mt of copper.
Spur is hosted in equivalent Late Ordovician aged geology of the Molong Belt within the wider Lachlan Fold Belt.
Brightstar Resources (ASX:BTR)
On the back of a run of positive news from its Sandstone Hub gold project in WA, Brightstar Resources has moved forward by 8.34% to 52c.
The gold potential at the 1.5Moz for 1.5g/t Sandstone project has been enhanced with more high-grade results from RC drilling at the Lord Nelson, Havilah and Bull Oak deposits.
This drilling is part of BTR's 2025 exploration strategy to aggressively drill out the historically underexplored project, targeting a resource upgrade in 2H 2025 including maiden ore reserves to support a pre-feasibility study.
The latest ~3,800m RC drilling program at Lord Nelson was aimed at infilling inside the conceptual pit shell to upgrade the resource classification to indicated.
Best assays from Lord Nelson include:
32m at 3.44g/t gold from 200m, including 17m at 5.44g/t from 215m;
18m at 2.50g/t from 236m, including 1m at 13.9g/t from 237m; and
10m at 2.94g/t from 214m, including 2m at 5.79g/t from 221m.
Results from a 6-hole, 730m program at Havilah deposit include 3m at 11.4g/t gold from 129m, including 1m at 29.5g/t from 131m and confirm that the high-grade mineralisation remains open down-plunge for further follow up targeting resource growth.
Results from Bull Oak deposit include:
19m at 1.18g/t gold from 177m, including 1m at 10.1g/t from 192m, within a broader, unconstrained intercept of 106m at 0.6g/t from 134m; and
2m at 8.93g/t from 112m, including 1m at 13.7g/t from 112m, within a broader, unconstrained intercept of 167m at 0.59g/t from 11m.
Brightstar Resources (ASX:BTR) aims to get the project into production asap, with first gold anticipated as soon as 2028.
Drilling continues with an RC rig in action at the Indomitable Camp in Sandstone and results pending from a ~6,000m program at the Yunndaga deposit (Menzies Hub), completed by a second rig.
Koonenberry Gold (ASX:KNB)
Koonenberry Gold remains in demand after last week making it six-for-six with visible gold during initial diamond drilling at its Enmore project in northeast New South Wales.
With the sixth diamond hole in the program again returning visible gold, the company has risen another 22.4% to a daily high of 9.3c on volume of more than 48 million. This represents a new high of more than two years.
The hole demonstrates that mineralisation extends from surface to 300m vertically, 80m laterally and 40m along strike of the zone reported in assays from the third hole.
While assays from the fourth, fifth and sixth holes are upcoming, the highest grade assay to date is 5m at 11.7g/t gold in the second hole.
Despite the project's location in the New England Fold Belt, which has an endowment of more than 35 million ounces of gold …. Enmore remains relatively unexplored.
Enmore is only about 25km from the 1.7Moz Hillgrove gold and antimony mine.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Health Check: Cochlear's ear-nings downgrade is not what investors wanted to hear
Cochlear downgrades full-year profit expectations, citing sluggish sound processor sales Mesoblast eyes second US drug approval sooner rather than later Who's for a bargain biotech … or three? Cochlear (ASX:COH) is banking on the rollout of new hearing devices to bolster earnings after today downgrading its full-year earnings expectations. The fourth biggest ASX-listed biotech, Cochlear now expects underlying net earnings of $390-400 million, compared with February's guidance at the 'lower end' of $410-430 million. Let's call it a 5% downgrade. Management had expected a single-digit decline in its services revenue – sound processors and the like – but now expects a fall in the high-single digit territory. The problem is that Nucleus 8 sound processor sales grew strongly post launch, but the buzz has abated. Users are unwilling to upgrade to tweaked variants such as the Kanso 'off the ear' processor. 'We continue to work on identifying and connecting with recipients who could benefit from the latest sound processing technology,' the company says. 'These initiatives, combined with the introduction of are expected to lift services revenue in the 2025-26 year.' Meanwhile, sales of the Cochlear implants remain robust and should increase by 10 per in the current year. But growth is weighted to emerging markets. 'Growth in the higher value developed markets has been impacted by slower-than-expected market growth and a small loss of market share in a few countries.' Smart implant launch dulls the pain Not all Cochlear's news was negative. Also today, Cochlear launched its Nucleus Nexa System, 'the world's first and only smart cochlear implant'. The device enables users to upgrade the firmware for both the implant and the related Nucleus 8 Nexa sound processor. Cochlear CEO Dig Howitt says Nexa results from 20 years of research and development. 'Similar to smartphones, the implant firmware can be updated to enable new features and access to future innovations.' After dipping 8% in early trade, Cochlear shares by noon were slightly higher ... so go figure. Buoyant Bioxyne bolsters revenue Bioxyne (ASX:BXN) this morning had a more encouraging update, upping full-year revenue expectations from $25 to $28 million. That's a 200% jump on last year's run rate. Bioxyne sells consumer health products – notably cannabis derived ones such as medicinal 'gummies'. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into producing psychedelic compounds for therapeutic use. The company was granted Australia's first Good Manufacturing Practice licence to produce psilocybin and MDMA ('molly', or ecstasy) Management cites Australian pharmaceutical manufacturing and supply as the key growth driver. "The company is making significant progress in Germany and the UK and will provide a market update shortly." Telix launches second imaging product Telix Pharmaceuticals (ASX:TLX) has launched its second commercial product in the US, also for prostate cancer. The tool, Gozellix, is a kit for preparing an injection of gallium-68 (gozetotide) to detect the tell-tale prostate-specific membrane antigen. The agent is relevant for prostate cancer patients suspected metastases and are candidates for initial definitive therapy. It is also intended for patients with suspected recurrence of prostate cancer based on an elevated serum prostate-specific antigen level. The US Food and Drug Administration (FDA) approved Gozellix in March 2025. The company says Gozellix has a shelf life of up to six hours, which makes it more flexible to use than other products based on the gallium-68 isotope. The company also claims Gozellix is 90% accurate in detecting metastases at the initial stage. In December 2021 the FDA approved Telix's first product, Illucix, which is also gallium-68 based. In calendar 2024 Telix reaped $783 million of revenue from Illucix, 70% higher. US Mesoblast-off for second product? Stem cell therapy developer Mesoblast (ASX:MSB) is confident the FDA will allow accelerated approval of its heart disease drug candidate, Revascor. The agency last December approved Mesoblast's Ryoncil for childhood graft-versus-host disease. That entrenches Ryoncil in the Biotech Hall of Fame as the first and only FDA-approved mesenchymal stromal stem cell product for any indication. Revascor is intended for the much larger market of patients with ischemic chronic heart failure, reduced ejection fraction and inflammation. In the first week of June, Mesoblast held a Type B meeting with FDA to discuss components of a potential filing for marketing approval. 'There was general alignment on items regarding chemistry, manufacturing and controls, potency assays for commercial product release and proposed design and primary endpoint for the confirmatory trial post-approval,' Mesoblast says. 'The company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing.' What's in the brokers' bargain bin? Investors are undervaluing at least three ASX biotech, according to broking analysts. Bell Potter rates Radiopharm Theranostics (ASX:RAD) a buy, citing an 'exceptionally positive outlook'. This follows yesterday's announcement of US Food and Drug Administration fast track approval for its metastatic brain cancer radiotherapy, RAD101. Radiopharm is trialling RAD101 in a 30 patient, phase II effort across five eastern Australian sites. Headline results are due in late 2025 – 'earlier than anticipated'. Bell Potter values the stock at 2.6 cents, compared with yesterday's close of half a cent. Macquarie Equities opines the Monash IVF Group (ASX:MVF) share sell off has been overdone following a second embryo mix-up 'incident'. In a note titled 'bargain hunting' – there's a clue – the firm values the stock at $1.30 a share, implying 100% upside. This is despite the shares recovering 10% this morning after CEO Michael Knaap resigned, leaving CFO Malik Jainudeen to fill the hot seat temporarily. Finally, Morgans values Imricor Medical Systems (ASX:IMR) at $2.28, a 40% increment on the current price. The company has developed the world's first cardiac ablation device that can be guided by magnetic resonance imaging. This week Imricor won European (CE Mark) approval for its Northstar Mapping System, a key component of its offering.
News.com.au
an hour ago
- News.com.au
Lunch Wrap: ASX rides oil surge, but Cettire sinks 30pc as luxury demand tanks
ASX holds gains as oil stocks fire up Cettire crashes 26% as luxury demand tanks Monash IVF climbs after CEO steps down The ASX 200 opened higher this morning and by lunchtime AEST it was still clinging onto a 0.20% gain. But while the rest of the market was lethargic, energy stocks were wide awake and charging this morning. Oil jumped over 4% overnight, driven by shrinking US stockpiles and fresh Middle East tension bubbling back to the surface. The US is apparently pulling embassy staff as Iran threatens to hit US bases in the region if nuclear negotiations fall through. The news has lit a fire under the local names this morning, with Woodside Energy Group (ASX:WDS) jumping over 2% and Santos (ASX:STO) tacking on 1.5%. Meanwhile, Trump said last night the US and China had struck a deal, with China expected to send over rare earths and magnets, and in return, the US will let Chinese students back into unis. But markets weren't exactly reassured. 'The uncertainty doesn't help,' said Nick Twidale at AT Global Markets Australia. 'And his overall comments overnight have led to more uncertainty for the market rather than the clarity we were hoping for.' Back home, this is where things stood at about 12:40pm AEST: In the large caps space, Cochlear (ASX:COH) was up 1.5% despite downgrading earnings guidance. It's now expecting between $390m and $400m, down from its earlier forecast, citing softer growth in developed markets. Implants, however, are still tipped to grow 10% this year. AGL Energy (ASX:AGL) dipped 1.5% after confirming it's having an early poke around what to do with its 20% stake in Tilt Renewables. Just 'preliminary investigations", said the company. ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for June 12 : Security Description Last % Volume MktCap ADD Adavale Resource Ltd 0.002 50% 1,261,565 $2,287,279 SFG Seafarms Group Ltd 0.002 50% 2,704,629 $4,836,599 RML Resolution Minerals 0.028 47% 71,723,563 $9,989,950 BLZ Blaze Minerals Ltd 0.004 33% 186,000 $4,700,843 DGR DGR Global Ltd 0.004 33% 1,922,063 $3,131,088 RAN Range International 0.002 33% 250,030 $1,408,935 RLC Reedy Lagoon Corp. 0.002 33% 599,068 $1,165,060 SRN Surefire Rescs NL 0.002 33% 5,580,186 $3,729,668 CDE Codeifai Limited 0.030 30% 2,400,533 $9,900,084 CTN Catalina Resources 0.005 25% 44,131 $9,704,076 EDE Eden Inv Ltd 0.003 25% 1,331,868 $8,219,762 HFY Hubify Ltd 0.010 25% 233,332 $4,089,090 JAV Javelin Minerals Ltd 0.003 25% 753,793 $12,252,298 MEM Memphasys Ltd 0.005 25% 88,464 $7,934,392 MMR Mec Resources 0.005 25% 897,010 $7,399,063 BXN Bioxyne Ltd 0.032 23% 24,279,435 $56,285,547 CLV Clover Corporation 0.500 22% 4,223,205 $68,469,730 SPD Southernpalladium 0.605 21% 210,309 $45,475,000 AHN Athena Resources 0.006 20% 91,054 $11,329,785 GGE Grand Gulf Energy 0.003 20% 714,148 $7,051,062 KPO Kalina Power Limited 0.006 20% 11,576 $14,664,849 JBY James Bay Minerals 0.655 19% 1,019,396 $39,523,424 Medicinal cannabis company Bioxyne (ASX:BXN) has upgraded its full-year revenue forecast to $28m (up from $25m), after a big first half and an even stronger second half expected. BXN says it see big growth locally, as well as in Germany and the UK. It says FY26 should see even more momentum as it pushes further into Europe. Nutritional ingredients supplier Clover Corp (ASX:CLV) expects its FY25 profit to come in around 20% above consensus, with sales also topping the $79 million forecast. It reckons the momentum will carry into FY26, with full results due out in September. Southern Palladium (ASX:SPD) has locked in $8 million from a share placement at 50 cents to help fast-track its Bengwenyama PGM project in South Africa. The raise was led by one of its biggest shareholders, who tipped in $4.6 million. The cash will go towards finalising its Definitive Feasibility Study. Meanwhile, Monash IVF Group (ASX:MVF) tried to hit the reset button. CEO Michael Knaap has stepped down after a second embryo mix-up this week, this time at its Clayton lab. Two bungles in three months is rough going for a company dealing in life's most sensitive business. MVF's shares rose 6% on the news. ASX SMALL CAP LOSERS Here are the worst performing ASX small cap stocks for June 12 : Code Name Price % Change Volume Market Cap ALV Alvo Minerals 0.021 -46% 2,632,293 $5,972,315 OB1 Orbminco Limited 0.001 -33% 2,151,730 $4,796,352 CTT Cettire 0.328 -30% 31,367,200 $177,275,772 HLX Helix Resources 0.002 -25% 2,002,454 $6,728,387 CLG Close Loop 0.052 -22% 2,772,694 $35,633,941 ARC ARC Funds Limited 0.096 -20% 5,500 $6,174,261 TGH Terragen 0.020 -20% 20,000 $12,625,429 1AD Adalta Limited 0.002 -20% 12,000 $2,516,766 AAU Antilles Gold Ltd 0.004 -20% 1,032,221 $11,556,840 OVT Ovanti Limited 0.002 -20% 8,595,935 $6,983,788 RGL Riversgold 0.004 -20% 35,000 $8,418,563 ROG Red Sky Energy. 0.004 -20% 55,000 $27,111,136 TMX Terrain Minerals 0.002 -20% 100,023 $5,621,392 EVE EVE Health Group Ltd 0.033 -18% 1,219,896 $5,274,509 BMO Bastion Minerals 0.003 -17% 4,529,092 $2,710,883 GES Genesis Resources 0.005 -17% 108,549 $4,697,048 ICG Inca Minerals Ltd 0.005 -17% 799,600 $9,458,340 IFG Infocusgroup Hldltd 0.005 -17% 531,286 $1,655,771 TON Triton Min Ltd 0.005 -17% 45,000 $9,410,332 KKO Kinetiko Energy Ltd 0.042 -16% 18,420 $71,629,255 AM5 Antares Metals 0.006 -14% 4,253,015 $3,603,970 AQX Alice Queen Ltd 0.003 -14% 991 $4,373,740 AS2 Askarimetalslimited 0.006 -14% 3,125,202 $2,829,195 Online luxury fashion retailer Cettire (ASX:CTT) crashed after it revealed soft sales, sliding margins, and a nasty FX hit, with US demand dropping off and the June quarter already looking grim. The company said luxury isn't flying like it used to. With cash burning fast and the balance sheet looking thinner by the week, investors reckon a cap raise might be imminent. IN CASE YOU MISSED IT A QMines (ASX:QML) drilling campaign at Develin Creek is rapidly advancing to expand high-grade copper mineralisation and convert inferred resources near Rockhampton in Queensland. Rhythm Biosciences (ASX:RHY) Rhythm Biosciences (ASX:RHY) has published a study in peer-reviewed open access journal PLoS One, validating its colorectal cancer risk assessment model and marking a major step forward in predictive cancer diagnostics. Silver Mines (ASX:SVL) is adding high-prospectivity, low-risk US precious metals exploration assets to complement its Australian portfolio. LAST ORDERS Melody Gold has exercised an option to process surface gold materials at the Horseshoe Metals (ASX:HOR) Horseshoe Lights copper-gold project in Western Australia, providing both tonnage-based payments and a fixed monthly $50,000 from the start of processing. Horseshoe retains its full rights to copper, mixed surface materials, and all subsurface materials at the project, and director Kate Stoney said it was a strategic step forward to capture early cash flow to help expedite the asset's redevelopment as the company ramps up activity. Titanium Sands (ASX:TSL) has confirmed the progress on environmental studies over its Mannar heavy mineral project in Sri Lanka with a recent site visit and advancements in addressing items raised earlier this year. TSL managing director Dr James Searle said the impact assessment was a very real and detailed study of the project area, and that each and every environmental concern would be addressed. 'It is expected the project will generate significant employment opportunities and long-term wealth for the community not just during the project but also ongoing post rehabilitation,' Dr Searle said. Golden Mile Resources (ASX:G88) has added close to $380,000 to the coffers from the ATO through a research and development tax incentive for work over its Quicksilver nickel-cobalt project near Lake Grace in WA in developing laterite processing technology. G88 managing director Damon Dormer welcomed the refund, saying it provides more funding for exploration over its Pearl copper project in Arizona, where it now awaits assays after wrapping up a maiden 10-hole RC campaign.
Mercury
an hour ago
- Mercury
Aus distressed sales plunge but one capital explodes a shock 36pc
Australia's distressed listings have fallen a solid 9.9pc year-on-year, but troubling signs are emerging in three capitals, one of which has just had a gut-wrenching 36pc monthly spike. National distressed listings figures by SQM Research saw a 4.2 per cent monthly fall emerge in May, dropping to 4,593 homes being put up in forced sales – a drop in the ocean compared to what economists were expecting overall but several capitals have seen big annual jumps. The latest figures have 1,311 homes up for distressed sale in Queensland, 1,127 in New South Wales, 1,033 in Victoria, 621 in Western Australia, 248 in South Australia, 117 in Tasmania, 102 in Northern Territory and 34 in ACT. But the concern lies in where those numbers have come from. MORE: Man pulls out 20m 'monster' in Aussie backyard Wallabies to wealth: Huge windfall looms for 25yo star MORE: Cash-strap student turns $40k to 38 homes Palaszczuk scores insane 684 per cent return on Brisbane property SQM Research head Louis Christopher said 'VIC's distressed listings were up 8.1 per cent over the year, 'while ACT was the only state to post a significant monthly rise at 36pc, now 13.3pc higher annually.' Queensland has consistently held the highest number of distressed listings hovering around 1,300, followed by NSW and Victoria which both sat around 1000 to 1200 in the past few months. But the Australian capital has seen shocking volatility in its numbers, with the current figure fluctuating after a 32.4pc monthly decrease in April, a 48pc monthly increase in March and a 13.6pc monthly increase in January. Victoria's 8.1pc annual rise in May comes after three consecutive months of concerning figures, with a 9.3pc annual rise in April, 8pc annually in March, and a significant yearly jump of 18.2pc in February. Annual figures are compared to the same month the previous year while monthly rises are against the month before. MORE: Shock twist as former Virgin CEO to tear down $17m mansion Inside slumlord's crumbling empire: derelict, unliveable, worth millions The ACT monthly surge comes as other states saw declines during May compared to April, led by WA (-9.6pc) and Qld (-5.5pc), while NSW dipped slightly by 0.4pc and VIC fell by 5.1pc. Mr Christopher said actual mortgagee sales made up about one fifth of current data, with around 500 homes nationally being sold after repossession, but a far bigger number were being forced to market before that situation came to a head. 'I think the banks are massaging the number,' he claimed. 'To do a mortgagee in possession is the final straw for a bank. So what often happens before that final straw is the banks will informally push the borrower to sell. So I'll basically make a phone call and say 'you don't sell your property by this day, we're going to.' 'So we think it's a better measurement that we're capturing. We believe we are capturing those ones where it's a bank that's pushing the borrower to sell informally.' SQM data incorporates a range of situations apart from mortgagee sales to properties pushed to market by divorce and deceased estates. Mr Christopher said Australia had survived the past two years of interest rate surges and cost of living spikes much better than expected. 'In truth, distress listings activity over the past two years has been lower than what we expected as a research house,' Mr Christopher said. 'Our expectation was that we would see distress listings activity get over 10,000 listings following the interest rate rise in 2022, and that didn't materialise.' MORE: Tradie's colossal 5.5m find in Aus backyard Million-dollar shock: Most Aussies now priced out of house market 'Now it is true that we have seen a pick-up in listings over that time in New South Wales and Victoria. In more recent times that pick-up has subsided, and levelled out, and in no state are really recording distress listings activities at alarming levels which would put downward pressure on housing prices.' Mr Christopher said the figures were below longer term average levels that SQM had seen. 'With the interest rate cuts we've had, and yet another likely next month, I think the outlook for distress activity is that they're going to keep falling.' He said the figures did 'jump around from month to month, that is true, so I do tend to like looking at the yearly numbers more and I like looking at the trend of the actual chart itself.' Mr Christopher said distress listings did offer opportunities to get in the market at a lower price. 'Not all of them, but quite a large proportion of them we find that there are opportunities for buyers in this list.' He said the hot ones moved 'real quick' – gone after a week. 'You can tell right away they were actually really, really good value ones because they've moved pretty quickly overall'. 'The housing market is far more efficient than what it was, say, 10, 20, 30 years ago, so bargains can be pinpointed pretty quickly if they're a genuine.' He said current distress levels were 'relatively benign' compared with other financial crisis situations faced by Australians in the past. 'They are commensurate and consistent with the low default rates that the banks have been reporting.' MORE REAL ESTATE NEWS
